tattooonmybrain.com
Biogen gives up on aducanumab (Aduhelm)
On January 31, Biogen put out a press release indicating that it “plans to reprioritize its resources in Alzheimer’s disease” by halting development and marketing of the anti-amyloid monoclonal ant…
